Answers are grounded in this paper and cite their sources.
Observational study evaluates ruxolitinib's safety and effectiveness in myelofibrosis, highlighting adverse drug reactions.
To evaluate the safety and effectiveness of ruxolitinib in patients with myelofibrosis (MF) in Japan. A multicenter, observational study of patients who received ruxolitinib for MF from July 2014. Of 892 patients (mean age: 70 years, 45.9% primary MF, ruxolitinib treatment median duration, 541.0 days), 67.7% had adverse drug reactions (ADRs) and 31.5% had serious ADRs. The most frequent ADRs were anemia and decreased platelet count. Incidences of ADRs by time of onset were 57.7%, 20.3%, 14.4%, 11.1%, 11.3%, 9.0%, and 1.8% from the treatment initiation to Day 182, and every 6 months thereafter until Day 1,093 or later, respectively. ADRs of special interest included myelosuppression (46.8%), infections (17.6%), hepatic impairment (13.5%), hemorrhagic events (10.2%), cardiac failure (2.5%), interstitial lung disease (1.5%), malignancy (1.4%) and tuberculosis (0.5%). Incidences of common ADRs were similar between patients with hepatic or renal impairment and patients without hepatic or renal impairment. At 6 months, spleen responses and symptom improvement were observed in 26.2% and 52.0% of patients, respectively. Median overall survival was not reached. In a real-world setting in Japan, ruxolitinib demonstrated a reasonable degree of effectiveness with no new safety concerns. Results were similar to those from clinical trials.
No takes yet. Share an insight, caveat, or question.
Aruga et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: